| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Charles River Laboratories Corp. |
| 251 Ballardvale Street, Wilmington, MA 01887 * (978) 658-6000 |
| Business Description | The company is a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development. |
| Offering Information Company has | |||
| Trading As | CRL (NYSE) | Industry | Pharmaceutical (SIC 2836) |
| Type of Stock Offered | Common Shares | Filing Date | 4/25/00 |
| Domestic Shares Offered | 14,000,000 | Offer Date | 6/22/00 |
| Foreign Shares Offered | 0 | Filing Range | $15.00 - $17.00 |
| Company Shares | 14,000,000 | Offer Price | $16.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $1.120 |
| Gross Proceeds | $224,000,000 | Selling | $0.670 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 32,320,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Donaldson, Lufkin & Jenrette Securities Corp. | Lead Manager | (212) 371-0641 |
| DLJDirect, Inc. | Co-manager | (800) 825-5723 |
| ING Baring Furman Selz | Co-manager | (212) 309-8200 |
| Lehman Brothers Incorporated | Co-manager | (212) 526-8100 |
| SG Cowen | Co-manager | (212) 495-6000 |
| U.S. Bancorp Piper Jaffray | Co-manager | (612) 342-6220 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/27/07 | 12/26/98 | 12/25/99 | ||||
| Revenues | - | - | 170.713 | 193.301 | 219.276 | - | - |
| Income from Oper. | - | - | 22.076 | 35.325 | 42.963 | - | - |
| Net Income | - | - | 15.340 | 23.378 | 17.124 | - | - |
| E.P.S | - | - | 1.490 | 2.270 | 1.660 | - | - |
| Revenue Growth (%) | - | - | 13.23 | 13.438 | - | ||
| Net Income Growth (%) | - | - | 52.40 | -26.75 | - | ||
| Oper. Profit Margin (%) | - | - | 12.93 | 18.27 | 19.59 | - | - |
| Net Profit Margin (%) | - | - | 8.99 | 12.09 | 7.81 | - | - |
| Cash Flow - Oper. | 37.57 | - | - | ||||
| Cash Flow - Inv. | -34.17 | - | - | ||||
| Cash Flow - Fin. | -11.50 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/25/00 | Financial Ratios | ||||
| Total Assets | 363.06 | Current Assets | 90.07 | Current Ratio | 1.29 |
| Total Liab. | 473.20 | Current Liab. | 69.74 | Debt Ratio | 130.34% |
| Total Equity | -110.14 | Working Cap. | 20.34 | Debt to Equity Ratio | - |
| Cash | 15.01 | Return on Assets | 4.72% | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to redeem a portion of outstanding senior subordinated notes, and to repay senior discount debentures, subordinated discount notes and a portion of bank debt. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Ropes & Gray |
| Bank's Law Firm | Davis, Polk & Wardwell |
| Registrar/Transfer Agent | State Street Bank and Trust Company |
| Auditor | Pricewaterhouse Coopers LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| DLJ Merchant Banking Partners II, L.P. | 73.60 | |
| Bausch & Lomb Incorporated | 12.50 | |
| Note: represents ownership of 5% or more prior to the offering. | ||